Preparing for the First Wave: Biosimilars at ASCO 2018

Posted by Max Kuehn on Sep 5, 2018 8:00:00 AM

As always, clinical innovation dominated the conversation at ASCO 2018, but many attendees also made time to attend sessions on value and financial burden, where biosimilars were a frequent topic. With more than 40 biosimilars already approved in the EU, and rituximab, trastuzumab and bevacizumab biosimilars approaching launch in the U.S., biosimilars will play a major role in the future oncology landscape. 

Read More